Compugen Ltd (CGEN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Compugen Ltd  (NASDAQ: CGEN)


Compugen Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Compugen Ltd's ROI in the fourth quarter of 2025?
Compugen Ltd achieved a return on average invested assets (ROI) of 29.84 % in its fourth quarter of 2025, this is above CGEN's average return on investment of -36.48%.
Compugen Ltd invested over the 12 months ending in its fourth quarter of 2025 $118 million

ROI has improved compared to -13.09% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 55 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 246, from total ROI ranking in the third quarter of 2025 at 3264.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM 26.81 % 15.91 % 13.68 % 23.72 % 15.95 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 132 132 79 132 93
Return On Investment (TTM) 29.84 % -13.09 % -14.38 % -13.79 % -15.24 %
CGEN's Overall Ranking # 246 # 3264 # # #
Seq. Investment Change TTM 8.93 % 9.9 % -4.13 % 10.49 % -0.43 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions 35 -14 -14 -14 -14

CGEN Company Profile >> Back to CGEN Roi Comparisons >> See Annual CGEN Return On Investment



Return On Investment CGEN's Ranking
Within: No.
Industry # 11
Sector # 56
Overall # 246

Return On Investment Statistics
High Average Low
26.32 %
-36.48 %
-113.71 %
(Dec 31 2025)   (Dec 31 2017)







Financial Statements
Compugen Ltd's IV. Quarter Investments $ 132 Millions CGEN's Balance sheet
Compugen Ltd's IV. Quarter Income $ 35 Millions Quarterly CGEN's Income Statement
CGEN's Income by Division See CGEN's Income by Division


CGEN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 132 93 95 81 115
Y / Y Investment Growth 41.75 % -1.72 % 16.34 % -29.29 % -9.96 %
Net Income in Millions 35 -14 -19 -34 -34
Y / Y Net Income Growth - - - - -
Annual Return On Investment 26.8 % -15.3 % -19.81 % -41.41 % -29.72 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 26.8 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CGEN's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CGEN's Competitors
Subscribers only: Roi for Compugen Ltd's Suppliers
Subscribers only: Return On Investment for CGEN's Customers

Other Ratios
CGEN's Roa CGEN's Inventory Turnover Ratio CGEN's Growth Rates CGEN's Dividend Statistics
CGEN's Profitability Ratios CGEN's Asset Turnover Ratio CGEN's Dividend Growth
CGEN's Roe CGEN's Valuation Ratios CGEN's Financial Strength Ratios CGEN's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Earth Science Tech Inc   78.43 %
Exelixis Inc   71.31 %
Entera Bio Ltd   63.91 %
Tg Therapeutics Inc   63.77 %
Aurinia Pharmaceuticals Inc   56.37 %
Pulmatrix Inc   53.09 %
Novavax inc   51.88 %
Gsk Plc  51.22 %
Q32 Bio Inc   50.33 %
Idexx Laboratories Inc  48.69 %
Theravance Biopharma inc   46.03 %
Elite Pharmaceuticals Inc   45.80 %
Enlivex Therapeutics Ltd  45.75 %
Galmed Pharmaceuticals Ltd   43.72 %
Abeona Therapeutics Inc   42.25 %
Alpha Tau Medical Ltd  42.04 %
Dariohealth Corp   41.31 %
Acadia Pharmaceuticals Inc   39.64 %
Medinotec Inc   37.45 %
Zevra Therapeutics Inc   36.78 %
Oramed Pharmaceuticals Inc  35.86 %
Ptc Therapeutics inc   35.12 %
Mettler toledo International Inc   34.74 %
Newgenivf Group Limited  32.05 %
Eli Lilly And Company  31.62 %
Indivior Pharmaceuticals Inc   31.00 %
Hutchmed china Limited  30.87 %
Medpace Holdings Inc   30.44 %
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %

Date modified: 2026-07-07T15:05:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.